Physician profile
James E Berman
NPI 1821047283
$11,063.68
in general payments reported to CMS, 2019-2025
36 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,394 · 2020: $532 · 2021: $1,185 · 2022: $1,382 · 2023: $1,788 · 2024: $1,915 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,290 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,290.17 |
| Education | $281.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $2,504.32 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Abbvie INC. | $1,744.37 | 2019-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $794.51 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $710.03 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $705.14 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $679.23 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $633.55 | 2019-2025 | |
| Dermavant Sciences, INC. | $341.75 | 2023-2024 | Vtama |
| Genzyme Corporation | $340.81 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $316.88 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $274.48 | 2021-2024 | Libtayo, Dupixent |
| Celgene Corporation | $250.14 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $208.22 | 2019-2020 | |
| Leo Pharma INC. | $167.48 | 2020-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $156.15 | 2022-2025 | Sotyktu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $130.49 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $120.55 | 2019 | |
| Prugen, INC. Pharmaceuticals | $112.36 | 2019 | |
| Galderma Laboratories, L.P. | $107.70 | 2019-2024 | Aklief |
| Dermira, INC. | $101.44 | 2019 | |
| Genentech USA, INC. | $94.59 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $75.38 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.59 | 2023-2024 | Cyltezo, Spevigo |
| Biofrontera INC. | $54.08 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Paratek Pharmaceuticals, INC. | $53.63 | 2024 | Nuzyra |
| Vyne Pharmaceuticals INC. | $52.89 | 2020-2021 | |
| Organon LLC | $50.59 | 2025 | Vtama |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Dusa Pharmaceuticals, INC. | $41.13 | 2019 | |
| Celltrion USA INC. | $30.43 | 2023 | Yuflyma |
| Arcutis Biotherapeutics, INC. | $19.35 | 2024 | Zoryve |
| Ani Pharmaceuticals, INC. | $17.96 | 2025 | Purified Cortrophin Gel |
| Incyte Corporation | $17.64 | 2022 | |
| Aclaris Therapeutics, INC. | $14.06 | 2019 | |
| Epi Health, LLC | $13.46 | 2021 | |
| Merck Sharp & Dohme LLC | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.